Guardant Health


Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Guardant Health
CIK #0001576280
SectorLife Sciences
IndustryServices-Medical Laboratories
Address505 Penobscot Dr
Redwood City, CA 94063
Source [EDGAR]
Market Cap, 13F ($)

We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood-based tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption of our tests, improve patient clinical outcomes, lower healthcare costs and accelerate drug development. In pursuit of our goal to manage cancer across all stages of the disease, we have launched our Guardant360 and GuardantOMNI tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 7,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers in the United States, and we believe it is the world's market leading comprehensive liquid biopsy test based on public disclosure of the number of comprehensive liquid biopsy tests sold in 2018. Our GuardantOMNI test, launched in 2017, has been used by our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Our LUNAR-1 assay was launched in 2018 for research use and in late 2019 for investigational use.

Precision oncology, as it is practiced today, is primarily focused on matching cancer patients to personalized treatments based on the underlying molecular profile of their tumors. There is a critical need to expand the scope of precision oncology to enable precise detection, monitoring and selection of the appropriate intervention as early in the disease state as possible. We believe a major challenge to achieving this is the limited access to cancer's molecular information. Traditionally, tissue tests that require physical access to tumor tissue through a biopsy or surgery have been used to gain access to this information. A tissue biopsy or surgery procedure, however, is often invasive, time-consuming and costly, which limits the utility of tissue tests. Tissue tests are also not feasible for certain applications such as screening for early detection of cancer.

Our liquid biopsy tests address many of the challenges of tissue biopsies. We believe our tests can expand the scope of precision oncology to earlier stages of the disease, improve patient outcomes and lower healthcare costs. We estimate the market opportunity for our current commercial and pipeline products is over $35 billion in the United States, comprising applications for clinicians and biopharmaceutical customers to address early to late-stage disease, including:

CIK Filing 2011 - 2021
[0001576280] 10-K
[0001576280] 10-Q
[0001576280] 3
[0001576280] 4
[0001576280] 5
[0001576280] 8-K
[0001576280] D
[0001576280] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Morgan Stanley Guardant Health Inc [2020-02-13] 5.3
Eltoukhy Helmy Guardant Health Inc [2020-02-12] 5.1
Talasaz Amirali Guardant Health Inc [2020-02-12] 4.8
Softbank Vision Fund AIV M1 LP Guardant Health Inc [2019-03-22] 32.4
Sequoia Capital US Venture Fund XIV LP Guardant Health Inc [2019-02-14] 9.0
SB Investment Advisers UK Ltd Guardant Health Inc [2019-02-13] 30.1
Khosla Ventures IV LP Guardant Health Inc [2019-02-13] 7.8
Eltoukhy Helmy Guardant Health Inc [2019-02-07] 6.3
Talasaz Amirali Guardant Health Inc [2019-02-07] 6.1
Form 3/4/5 Filer 2011-2021
Clark Ian T
Talasaz Amirali
Eltoukhy Helmy
Meresman Stanley J
Kaul Samir
SVF Bluebird Cayman Ltd
SB Investment Advisers UK Ltd
SVF Endurance Cayman Ltd
SVF Enterprise Cayman Ltd
Softbank Vision Fund AIV M1 LP
Bertocci Derek A
Gadde Vijaya
Jallal Bahija
Nishar Dipchand
Wiley Michael J
Lanman Richard B
Hilaly Aaref
Eggers Barry
LIEW Jeremy
Lightspeed Affiliates X LP
Lightspeed General Partner X LP
Lightspeed Ultimate General Partner X Ltd
Lightspeed Venture Partners X LP
Mhatre Ravi
NIEH Peter
Schaepe Christopher J
Lightspeed General Partner Select LP
Lightspeed Ultimate General Partner Select Ltd
Lightspeed Venture Partners Select LP
SC US Venture 2010 Management LP
SC US Venture XIV Management LP
Sequoia Capital Scout Fund II LLC
Sequoia Capital US Venture 2010-Seed Fund LP
Sequoia Capital US Venture Fund XIV LP
Sequoia Capital US Venture Partners Fund XIV Q LP
Sequoia Capital US Venture Partners Fund XIV LP
Sequoia Capital USV XIV HoldCo Ltd
Sandscape LLC
Khosla Ventures IV LP
Softbank Group Corp
Softbank Group Capital Ltd
Fullerton Management PTE Ltd
TLS Beta PTE Ltd
Temasek Holdings Private Ltd
Temasek Life Sciences Private Ltd
Khosla Vinod
Khosla Ventures Associates IV LLC
Khosla Ventures IV CF LP
VK Services LLC
OrbiMed Advisors LLC
Das-Young Leena
MM Shares Owned of 85.7 MM Total
Firm Period DFND Voting Shares
SB Investment Advisers UK Ltd [2020-09-30] DFND 0.0 14.0
Vanguard Group Inc [2020-09-30] SOLE 0.0 6.4
Morgan Stanley [2020-09-30] DFND 5.7 6.3
BlackRock Inc. [2020-09-30] SOLE 4.7 5.0
Viking Global Investors LP [2020-09-30] SOLE 3.9 3.9
Clearbridge Investments LLC [2020-09-30] SOLE 3.2 3.3
Jennison Associates LLC [2020-09-30] DFND 3.1 3.1
Nuveen Asset Management LLC [2020-09-30] DFND 2.9 2.9
Capital Research Global Investors [2020-09-30] DFND 2.0 2.0
Fred Alger Management Inc [2020-09-30] SOLE 1.9 1.9
Temasek Holdings (Private) Ltd [2020-09-30] DFND 1.6 1.6
Credit Suisse AG [2020-09-30] DFND 1.5 1.5
AllianceBernstein LP [2020-09-30] DFND 1.3 1.5
Franklin Resources Inc [2020-09-30] DFND 1.3 1.3
Price T Rowe Associates Inc /MD/ [2020-09-30] SOLE 0.4 1.3
Wells Fargo & Co/Mn [2020-09-30] DFND 0.7 1.3
Goldman Sachs Group Inc [2020-09-30] DFND 1.0 1.2
Coatue Management LLC [2020-09-30] DFND 1.1 1.1
BAMCO Inc /NY/ [2020-09-30] DFND 0.0 1.1
Massachusetts Financial Services Co /MA/ [2020-09-30] SOLE 1.0 1.0
FMR LLC [2020-09-30] DFND 0.1 1.0
Bank of America Corp /DE/ [2020-09-30] DFND 0.3 1.0
Allianz Asset Management GmbH [2020-09-30] DFND 0.9 0.9
Marshall Wace LLP [2020-09-30] SOLE 0.9 0.9
Geode Capital Management LLC [2020-09-30] DFND 0.9 0.9
State Street Corp [2020-09-30] DFND 0.7 0.9
HealthCor Management LP [2020-09-30] SOLE 0.8 0.8
Ameriprise Financial Inc [2020-09-30] DFND 0.0 0.7
Chevy Chase Trust Holdings, Inc. [2020-09-30] DFND 0.0 0.5
Citadel Advisors LLC [2020-09-30] DFND 0.5 0.5
Prev | Page 1 | Next
Terms | Privacy | Guide